What is Charming Medical's earnings per share (EPS)?

Charming Medical (MCTA) reported diluted earnings per share of $0.00 for fiscal year 2026. This represents a -100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Charming Medical Financials

MCTA

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE March

This page shows Charming Medical (MCTA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Charming Medical's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Charming Medical has an operating margin of -0.6%, meaning the company retains $-1 of operating profit per $100 of revenue. This results in a moderate score of 60/100, indicating healthy but not exceptional operating efficiency. This is down from 22.3% the prior year.

Growth

Charming Medical's revenue declined 22.7% year-over-year, from $6.2M to $4.8M. This contraction results in a growth score of 10/100.

Leverage

100

Charming Medical carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Charming Medical's current ratio of 1.89 indicates adequate short-term liquidity, earning a score of 54/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Charming Medical generated -$1.2M in operating cash flow, capex of $340K consumed most of it, leaving -$1.6M in free cash flow. This results in a low score of 13/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Charming Medical earns a strong -0.4% return on equity (ROE), meaning it generates $-0 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 80/100. This is down from 2435.0% the prior year.

Altman Z-Score Safe

64.60

Charming Medical scores 64.60, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($497.2M) relative to total liabilities ($4.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Charming Medical passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

53.69x

For every $1 of reported earnings, Charming Medical generates $53.69 in operating cash flow (-$1.2M OCF vs -$23K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1.9x

Charming Medical earns $-1.9 in operating income for every $1 of interest expense (-$29K vs $16K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$4.8M

YoY-22.7%

Charming Medical generated $4.8M in revenue in fiscal year 2026. This represents a decrease of 22.7% from the prior year.

EBITDA

$187K

YoY-88.7%

Charming Medical's EBITDA was $187K in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 88.7% from the prior year.

Net Income

-$23K

YoY-101.9%

Charming Medical reported -$23K in net income in fiscal year 2026. This represents a decrease of 101.9% from the prior year.

EPS (Diluted)

$0.00

YoY-100.0%

Charming Medical earned $0.00 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$1.6M

YoY-1224.2%

Charming Medical generated -$1.6M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 1224.2% from the prior year.

Cash & Debt

$4.7M

YoY+475.3%

Charming Medical held $4.7M in cash against $186K in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

99.3%

YoY-0.5pp

Charming Medical's gross margin was 99.3% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 0.5 percentage points from the prior year.

Operating Margin

-0.6%

YoY-22.9pp

Charming Medical's operating margin was -0.6% in fiscal year 2026, reflecting core business profitability. This is down 22.9 percentage points from the prior year.

Net Margin

-0.5%

YoY-19.7pp

Charming Medical's net profit margin was -0.5% in fiscal year 2026, showing the share of revenue converted to profit. This is down 19.7 percentage points from the prior year.

Return on Equity

-0.4%

YoY-2435.5pp

Charming Medical's ROE was -0.4% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 2435.5 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$340K

YoY+18.1%

Charming Medical invested $340K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 18.1% from the prior year.

MCTA Income Statement

Metric	FY26	FY25	FY24
Revenue	$4.8M-22.7%	$6.2M+3.4%	$6.0M
Cost of Revenue	$35K+127.0%	$16K+37.4%	$11K
Gross Profit	$4.8M-23.1%	$6.2M+3.4%	$6.0M
R&D Expenses	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A
Operating Income	-$29K-102.1%	$1.4M+37.7%	$1.0M
Interest Expense	$16K-24.3%	$21K-19.9%	$26K
Income Tax	$156K-33.9%	$236K+29.9%	$182K
Net Income	-$23K-101.9%	$1.2M+54.2%	$778K
EPS (Diluted)	$0.00-100.0%	$0.08+60.0%	$0.05

Metric	Q4'26	Q4'25
Revenue	N/A	N/A
Cost of Revenue	N/A	N/A
Gross Profit	N/A	N/A
R&D Expenses	N/A	N/A
SG&A Expenses	N/A	N/A
Operating Income	N/A	N/A
Interest Expense	N/A	N/A
Income Tax	N/A	N/A
Net Income	N/A	N/A
EPS (Diluted)	N/A	N/A

MCTA Balance Sheet

Metric	FY26	FY25	FY24
Total Assets	$9.9M+84.3%	$5.4M	N/A
Current Assets	$8.2M+142.8%	$3.4M	N/A
Cash & Equivalents	$4.7M+475.3%	$817K-61.2%	$2.1M
Inventory	$26K-4.4%	$27K	N/A
Accounts Receivable	$201K-49.1%	$396K	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$4.7M-11.7%	$5.3M	N/A
Current Liabilities	$4.3M-12.5%	$4.9M	N/A
Long-Term Debt	$186K	N/A	N/A
Total Equity	$5.2M+10421.2%	$49K+104.3%	-$1.1M
Retained Earnings	$97K-19.0%	$119K	N/A

Metric	Q4'26	Q4'25
Total Assets	$9.9M+84.3%	$5.4M
Current Assets	$8.2M+142.8%	$3.4M
Cash & Equivalents	$4.7M+475.3%	$817K
Inventory	$26K-4.4%	$27K
Accounts Receivable	$201K-49.1%	$396K
Goodwill	N/A	N/A
Total Liabilities	$4.7M-11.7%	$5.3M
Current Liabilities	$4.3M-12.5%	$4.9M
Long-Term Debt	$186K	N/A
Total Equity	$5.2M+10421.2%	$49K
Retained Earnings	$97K-19.0%	$119K

MCTA Cash Flow Statement

Metric	FY26	FY25	FY24
Operating Cash Flow	-$1.2M-385.5%	$426K+44.2%	$295K
Capital Expenditures	$340K+18.1%	$288K+36.5%	$211K
Free Cash Flow	-$1.6M-1224.2%	$138K+63.1%	$85K
Investing Cash Flow	-$179K+92.0%	-$2.2M-958.6%	-$211K
Financing Cash Flow	$5.3M+915.2%	$521K+420.5%	$100K
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q4'26	Q4'25
Operating Cash Flow	N/A	N/A
Capital Expenditures	N/A	N/A
Free Cash Flow	N/A	N/A
Investing Cash Flow	N/A	N/A
Financing Cash Flow	N/A	N/A
Dividends Paid	N/A	N/A
Share Buybacks	N/A	N/A

MCTA Financial Ratios

Metric	FY26	FY25	FY24
Gross Margin	99.3%-0.5pp	99.8%-0.1pp	99.8%
Operating Margin	-0.6%-22.9pp	22.3%+5.6pp	16.8%
Net Margin	-0.5%-19.7pp	19.3%+6.3pp	12.9%
Return on Equity	-0.4%-2435.5pp	2435.0%	N/A
Return on Assets	-0.2%-22.6pp	22.4%	N/A
Current Ratio	1.89+1.2	0.68	N/A
Debt-to-Equity	0.04-107.7	107.76	N/A
FCF Margin	-32.4%-34.6pp	2.2%+0.8pp	1.4%

Metric	Q4'26	Q4'25
Gross Margin	N/A	N/A
Operating Margin	N/A	N/A
Net Margin	N/A	N/A
Return on Equity	N/A	N/A
Return on Assets	N/A	N/A
Current Ratio	1.89+1.2	0.68
Debt-to-Equity	0.04-107.7	107.76
FCF Margin	N/A	N/A

Frequently Asked Questions

What is Charming Medical's annual revenue?

Charming Medical (MCTA) reported $4.8M in total revenue for fiscal year 2026. This represents a -22.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Charming Medical's revenue growing?

Charming Medical (MCTA) revenue declined by 22.7% year-over-year, from $6.2M to $4.8M in fiscal year 2026.

Is Charming Medical profitable?

No, Charming Medical (MCTA) reported a net income of -$23K in fiscal year 2026, with a net profit margin of -0.5%.

What is Charming Medical's EBITDA?

Charming Medical (MCTA) had EBITDA of $187K in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Charming Medical have?

As of fiscal year 2026, Charming Medical (MCTA) had $4.7M in cash and equivalents against $186K in long-term debt.

What is Charming Medical's gross margin?

Charming Medical (MCTA) had a gross margin of 99.3% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Charming Medical's operating margin?

Charming Medical (MCTA) had an operating margin of -0.6% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Charming Medical's net profit margin?

Charming Medical (MCTA) had a net profit margin of -0.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Charming Medical's return on equity (ROE)?

Charming Medical (MCTA) has a return on equity of -0.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Charming Medical's free cash flow?

Charming Medical (MCTA) generated -$1.6M in free cash flow during fiscal year 2026. This represents a -1224.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Charming Medical's operating cash flow?

Charming Medical (MCTA) generated -$1.2M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Charming Medical's total assets?

Charming Medical (MCTA) had $9.9M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Charming Medical's capital expenditures?

Charming Medical (MCTA) invested $340K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

What is Charming Medical's current ratio?

Charming Medical (MCTA) had a current ratio of 1.89 as of fiscal year 2026, which is generally considered healthy.

What is Charming Medical's debt-to-equity ratio?

Charming Medical (MCTA) had a debt-to-equity ratio of 0.04 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Charming Medical's return on assets (ROA)?

Charming Medical (MCTA) had a return on assets of -0.2% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Charming Medical's cash runway?

Based on fiscal year 2026 data, Charming Medical (MCTA) had $4.7M in cash against an annual operating cash burn of $1.2M. This gives an estimated cash runway of approximately 46 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Charming Medical's Altman Z-Score?

Charming Medical (MCTA) has an Altman Z-Score of 64.60, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Charming Medical's Piotroski F-Score?

Charming Medical (MCTA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Charming Medical's earnings high quality?

Charming Medical (MCTA) has an earnings quality ratio of 53.69x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Charming Medical cover its interest payments?

Charming Medical (MCTA) has an interest coverage ratio of -1.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Charming Medical?

Charming Medical (MCTA) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.